

# The future of computational pathology: expectations regarding the anticipated role of artificial intelligence in pathology by 2030

*Running Title: AI in pathology in 2030*

M Alvaro Berbis<sup>1,2,\*</sup>, David S. McClintock<sup>3</sup>, Andrey Bychkov<sup>4</sup>, Jerome Y Cheng<sup>5</sup>, Brett Delahunt<sup>6</sup>, Lars Egevad<sup>7</sup>, Catarina Eloy<sup>8</sup>, Alton B Farris III<sup>9</sup>, Filippo Frassetto<sup>10</sup>, Raimundo García del Moral<sup>11</sup>, Douglas J. Hartman<sup>12</sup>, Markus D Herrmann<sup>13</sup>, Eva Hollemans<sup>14</sup>, Kenneth A Iczkowski<sup>15</sup>, Aly Karsan<sup>16</sup>, Mark Kriegsmann<sup>17</sup>, Jochen K Lennerz<sup>18</sup>, Liron Pantanowitz<sup>19</sup>, Mohamed E. Salama<sup>20</sup>, John Sinard<sup>21</sup>, Mark Tuthill<sup>22</sup>, Jeroen Van der Laak<sup>23</sup>, Bethany Williams<sup>24</sup>, César Casado-Sánchez<sup>25,2</sup>, Víctor Sánchez-Turrión<sup>26,2</sup>, Antonio Luna<sup>27</sup>, José Aneiros-Fernández<sup>1,11</sup>, Jeanne Shen<sup>28,\*</sup>

<sup>1</sup> Department of R&D, HT Médica, San Juan de Dios Hospital, Córdoba, Spain

<sup>2</sup> Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain

<sup>3</sup> Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

<sup>4</sup> Department of Pathology, Kameda Medical Center, Chiba, Japan

<sup>5</sup> University of Michigan, Ann Arbor, MI, USA

<sup>6</sup> Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand

<sup>7</sup> Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

<sup>8</sup> Pathology Laboratory, Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal

<sup>9</sup> Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA

<sup>10</sup> Pathology Unit, Azienda Sanitaria Provinciale Catania, Gravina Hospital, Caltagirone, Italy

<sup>11</sup> Department of Pathology, San Cecilio Clinical University Hospital, Granada, Spain

<sup>12</sup> Department of Anatomic Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

<sup>13</sup> Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

<sup>14</sup> Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands

<sup>15</sup> Department of Pathology, Medical College of Wisconsin, Milwaukee, USA

<sup>16</sup> Department of Pathology & Laboratory Medicine, University of British Columbia, Michael Smith Genome Sciences Centre, Vancouver, Canada

<sup>17</sup> Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany

<sup>18</sup> Department of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA

<sup>19</sup> Department of Pathology, University of Michigan, Ann Arbor, MI, USA

<sup>20</sup> Department of Pathology, Sonic Healthcare, Austin, TX, USA

<sup>21</sup> Department of Pathology, Yale University School of Medicine, New Haven, CT, USA

<sup>22</sup> Department of Medical Oncology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK

<sup>23</sup> Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands

<sup>24</sup> Department of Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

<sup>25</sup> Department of Plastic and Reconstructive Surgery, La Paz University Hospital, Madrid, Spain.

<sup>26</sup> Department of General Surgery and Digestive Tract, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain

<sup>27</sup> Department of Integrated Diagnostics, HT Médica, Clínica Las Nieves, Jaén, Spain

<sup>28</sup> Department of Pathology and Center for Artificial Intelligence in Medicine & Imaging, Stanford University School of Medicine, Stanford, CA, USA

## (\*) Corresponding authors:

M Alvaro Berbis

Department of R&D, HT Médica, San Juan de Dios Hospital, Córdoba 14011, Spain

Faculty of Medicine, Autonomous University of Madrid, Madrid 28029, Spain

[a.berbis@htime.org](mailto:a.berbis@htime.org)

Jeanne Shen

Department of Pathology and Center for Artificial Intelligence in Medicine & Imaging

Stanford University School of Medicine, Stanford, CA 94305, United States of America

[jeannes@stanford.edu](mailto:jeannes@stanford.edu)

60 **Keywords:** Artificial intelligence; machine learning; digital pathology; computational pathology;  
61 anatomic pathology; pathologist workflow

62

63

## 64 **ABSTRACT**

65

66 **Background:** Artificial intelligence (AI) is rapidly fueling a fundamental transformation in the practice of  
67 pathology. However, AI's clinical integration remains challenging, with no AI algorithms to date enjoying  
68 routine adoption within typical anatomic pathology (AP) laboratories. This survey gathered current  
69 expert perspectives and expectations regarding the role of AI in AP from those with first-hand  
70 computational pathology and AI experience.

71 **Methods:** Perspectives were solicited using the Delphi method from 24 subject matter experts between  
72 December 2020 and February 2021 regarding the anticipated role of AI in pathology by the year 2030.  
73 The study consisted of three consecutive rounds: 1) an open-ended, free response questionnaire  
74 generating a list of survey items; 2) a Likert-scale survey scored by experts and analyzed for  
75 consensus; and 3) a repeat survey of items not reaching consensus to obtain further expert consensus.

76 **Findings:** Consensus opinions were reached on 141 of 180 survey items (78.3%). Experts agreed that  
77 AI would be routinely and impactfully used within AP laboratory and pathologist clinical workflows by  
78 2030. High consensus was reached on 100 items across nine categories encompassing the impact of  
79 AI on (1) pathology key performance indicators (KPIs) and (2) the pathology workforce and specific  
80 tasks performed by (3) pathologists and (4) AP lab technicians, as well as (5) specific AI applications  
81 and their likelihood of routine use by 2030, (6) AI's role in integrated diagnostics, (7) pathology tasks  
82 likely to be fully automated using AI, and (8) regulatory/legal and (9) ethical aspects of AI integration in  
83 pathology.

84 **Interpretation:** This is the first systematic consensus study detailing the expected short/mid-term  
85 impact of AI on pathology practice. These findings provide timely and relevant information regarding  
86 future care delivery in pathology and raise key practical, ethical, and legal challenges that must be  
87 addressed prior to AI's successful clinical implementation.

88

## 89 **Funding:**

90 This research received no specific grant from any funding agency in the public, commercial, or not-for-  
91 profit sectors.

92

93

94

## 95 INTRODUCTION

96  
97 By virtue of its ability to "learn" from large volumes of electronic health record and image data without  
98 explicit programming, machine learning and artificial intelligence (AI) are set to fuel an unprecedented  
99 transformation in healthcare. In hospitals and clinics of the future, AI will become a cornerstone in the  
100 way care is delivered, contributing to more accurate diagnoses, increasingly agile, cost-effective, and  
101 standardized clinical workflows, and highly effective and personalized treatments.<sup>1,2</sup> Excitement and  
102 expectations regarding the potential of AI to revolutionize healthcare have continued to build, as  
103 evidenced by the growing list of medical AI publications in the form of original research articles, review  
104 papers, health policy reports, white papers and consensus recommendations from professional  
105 societies, and coverage in the popular media.<sup>1-16</sup> A recent survey of English-language articles indexed  
106 in PubMed showed a significant increase in the volume of medical AI research publications, from just  
107 203 articles in 2005 to 12,563 in 2019.<sup>3</sup>

108  
109 Pathology has attracted growing attention as an image-rich specialty likely to be strongly impacted by  
110 recent advances in AI. The development of machine learning-based tools for automated image analysis  
111 has led to a surge in AI applications promising to revolutionize current pathology workflows, as well as  
112 the advent of a new field, computational pathology.<sup>7</sup> Between the years 2010-2020, approximately 23%  
113 (3,398) of all medical AI research publications were in pathology, making it the number one most-  
114 published specialty among the 17 specialties surveyed.<sup>3</sup> A recent survey of the patent landscape from  
115 the years 1974–2021 yielded 523 patents relevant to the application of AI to digital pathology, with the  
116 primary application areas being whole-slide image (WSI) acquisition, segmentation, classification, and  
117 object detection.<sup>17</sup> AI has been applied to several popular tasks in anatomic pathology (AP), including  
118 diagnosis, prognostication, and biomarker quantification, with key examples being automated  
119 assessment of prognostic biomarkers such as Ki-67 in breast cancer,<sup>18-20</sup> automated tumor grading in  
120 prostate cancer,<sup>21-25</sup> and diagnosis of metastatic breast cancer in lymph nodes.<sup>26-29</sup> Other recently-  
121 explored AI applications in pathology have included tools for optimizing clinical laboratory workflows,  
122 such as automated quality control (QC).<sup>30-32</sup>

123  
124 Much of the growth in computational pathology has been facilitated by the increased adoption of digital  
125 pathology, providing large amounts of WSI data as a prerequisite for practical AI model development  
126 and validation.<sup>33</sup> Concurrently, use of digital workflows within pathology has provided practices with  
127 new platforms for testing and integrating computational pathology tools within AP workflows, generating  
128 greater interest in AI from pathologists and pathology trainees. A 2018 voluntary survey of 487  
129 international pathologists and pathology trainees revealed a generally positive attitude towards AI, with

130 nearly 75% expressing interest/excitement regarding the integration of AI tools into diagnostic  
131 pathology.<sup>34</sup> Furthermore, 80% of respondents predicted the integration of AI-based assistance into AP  
132 workflows within the next 5–10 years.<sup>34</sup> Numerous reviews have been published on the emerging and  
133 future applications of pathology AI to cancer diagnosis, prognostication, and treatment response  
134 prediction, metastasis detection in lymph nodes, single and multiplex biomarker quantification, tumor  
135 content/cellularity assessment for molecular testing, mutation status prediction, and a multitude of other  
136 tasks in pathology.<sup>35–45</sup>

137  
138 Despite the recent progress and enthusiasm surrounding the application of AI to pathology, few  
139 algorithms are currently in routine clinical use,<sup>37,46</sup> with a dearth of prospective multi-center, randomized  
140 trials present evaluating the impact of these algorithms in clinical settings.<sup>47,48</sup> Further, ethical concerns  
141 have been raised regarding potential patient data privacy breaches, biased datasets producing  
142 systemic algorithmic bias, potential harm related to erroneous or misleading AI-generated outputs, and  
143 exacerbation of healthcare disparities due to unequal access to AI.<sup>49</sup> All of these factors, along with  
144 hurdles related to regulatory approval and reimbursement for AI products, have contributed to a  
145 significant AI "translation gap" in pathology.<sup>37</sup> While much has been written regarding the various  
146 opportunities and challenges surrounding AI in pathology, to date no systematic survey of opinions  
147 exists regarding the direct role of AI in pathology from the short to medium term perspective (the next  
148 decade) from those with dedicated expertise in digital and computational pathology. To address this  
149 knowledge gap, we conducted a consensus survey to gain detailed insight into the current challenges,  
150 expectations, and perspectives surrounding the role of AI in pathology, as seen from the point of view  
151 of an international panel of clinically active "early adopters" with hands-on experience developing and  
152 evaluating the clinical performance and utility of AI algorithms. For the survey, we chose to apply the  
153 Delphi method, a robust and widely accepted tool in medicine for building consensus among experts  
154 that has been shown to outperform standard statistical methods.<sup>50,51</sup>

155  
156 A Delphi study involves a panel of experts who rate a series of statements, usually in a binary (e.g.,  
157 agree/disagree) or semi-quantitative (e.g., Likert scale) manner. These statements might be produced  
158 after a systematic literature search or by surveying the same experts through a preliminary survey with  
159 open-ended questions (typically referred to as "Round 1"). Rating of statements is done over multiple  
160 consecutive rounds, during which the statements reaching the consensus criterion are omitted from  
161 subsequent rounds. Raters are then invited to reconsider their responses based on the group's mean  
162 or median ratings from previous rounds. Studies are typically terminated when consensus has been  
163 reached, responses are stable, or after a pre-fixed number of rounds (usually two)<sup>52</sup> to prevent expert  
164 fatigue. In contrast to typical single-round surveys, the Delphi technique relies on both the

165 anonymization of responses to avoid bias and the use of experts and structured communication  
166 through an iterative pathway to reach more reliable conclusions.<sup>53</sup>

167

168 The goals of our study were to: 1) investigate the expected impact of AI on pathology; 2) forecast the  
169 extent of clinical AI implementation in the specialty by the end of this decade; and 3) provide specific  
170 insights into which technical, legal, regulatory, and ethical aspects of AI integration will require the most  
171 attention from pathology laboratories in the coming years. We expect the results of this study to be of  
172 broad interest to practicing pathologists, pathology trainees, pathology assistants and laboratory  
173 technicians, patients, physicians from other medical specialties, professional societies, hospital  
174 administrators, regulatory bodies, and researchers in academia, industry, and government.

175

## 176 **MATERIALS AND METHODS**

### 177 *Expert Panel Recruitment*

178 Candidates for the expert panel were selected by the research team using the following eligibility  
179 criteria: 1) professionals working within the specialty of pathology (anatomic and/or laboratory  
180 medicine) with an MD (or equivalent medical degree, such as an MBBS) and/or PhD, and 2) authorship  
181 of at least one peer-reviewed publication in the area of CPath/AI within the four years preceding the  
182 study (2016–2020) indexed in PubMed.

183

184 Invitations to participate in the study were sent in December 2020 to 39 candidates meeting the  
185 selection criteria. A total of 24 experts (60%) accepted and completed all three rounds of the survey.  
186 Detailed characteristics of the panelists are summarized in **table 1**. The majority of experts were  
187 practicing in North America (54%), with the remainder practicing in Europe, Japan, and New Zealand.  
188 The panelists were distributed across 10 different pathology subspecialties, with a third of panelists  
189 explicitly specializing in informatics, computational pathology, and/or digital pathology. Finally, the  
190 range of years in professional practice was mostly spread evenly across the panelists, with the majority  
191 having been in practice for 11–20 years (33%).

192

193 **Table 1.** Characteristics of the panelists

Categories	n (%)
<i>Country of residence</i>	
United States of America	12 (50%)
The Netherlands	2 (8.3%)
Spain	2 (8.3%)


United Kingdom	1 (4.2%)
Germany	1 (4.2%)
Italy	1 (4.2%)
Sweden	1 (4.2%)
Portugal	1 (4.2%)
Canada	1 (4.2%)
Japan	1 (4.2%)
New Zealand	1 (4.2%)
<i>Area of subspecialization (multiple responses possible)</i>	
Informatics, computational pathology, digital pathology	8 (33.3%)
Hematopathology	4 (16.7%)
Genitourinary pathology	3 (12.5%)
Gastrointestinal pathology	3 (12.5%)
Endocrine pathology	2 (8.3%)
Dermatopathology	2 (8.3%)
Surgical pathology	2 (8.3%)
Molecular pathology	2 (8.3%)
Thoracic pathology	1 (4.2%)
Bone & soft tissue pathology	1 (4.2%)
<i>Years of experience</i>	
0–10	7 (29.2%)
11–20	8 (33.3%)
21–30	7 (29.2%)
31–40	2 (8.3%)

194

195

#### 196 *Delphi Study Development*

197 To obtain a reliable consensus of opinions, the Delphi study was conducted over three rounds via a  
198 series of detailed questionnaires combined with controlled opinion feedback.<sup>54</sup> The flowchart for the  
199 study is summarized in **figure 1**.



200  
201 **Figure 1.** Flowchart illustrating the process of the present Delphi study  
202

203  
204 In Round 1, a preliminary review of the pathology AI literature, along with the research team's empirical  
205 experience, was used to generate an open-ended questionnaire containing a set of 12 questions  
206 geared toward eliciting the ideas and opinions of the expert panelists regarding the following three  
207 topics: 1) forecasting the future of AI in pathology, 2) specific AI applications in pathology, and 3) ethical  
208 and regulatory aspects (**table 2**). The panelists' responses to these open-ended questions were  
209 combined and distilled (all original answers were analyzed, and similar answers within the same  
210 category were grouped and summarized into a single statement, with the original wording used by the  
211 panelists reproduced wherever possible) into a series of questionnaire statements used in the  
212 subsequent survey rounds.

213  
214 **Table 2.** Round 1 questions

<b>Section 1: Forecasts about the future</b> (please answer according to what you believe will happen by 2030, instead of what you would like to see happen)	
1	On what key performance indicators related to pathology do you believe AI will have a positive impact?
2	How do you think AI will impact the pathology workforce (jobs which will be created and jobs which will be destroyed) by 2030?
3	What new tasks will pathologists be involved in?



4	What new tasks will pathology technicians be involved in, or what existing tasks will they take on more responsibility for?
5	Which tasks currently performed by pathologists will be fully automated by AI by 2030?
<b>Section 2: Applications of AI in pathology</b> (please cite any existing or potential AI-based tools which, in your opinion, would bring value to pathologists. Be as specific as possible)	
6	In what ways can AI be used to improve diagnostic precision?
7	In what ways can AI be used to speed up or facilitate the work of pathologists?
8	What examples of AI tools or applications would bring value to the analysis and interpretation of histological images?
9	What examples of AI tools or applications would bring value to other aspects of the laboratory workflow?
10	In what ways can AI be used to bring value to integrated diagnostics? (integrated diagnostics refers to the convergence of two or more diagnostic techniques, such as pathology, radiology, genomics)
<b>Section 3: Ethical and regulatory aspects</b>	
11	What regulatory challenges will have to be overcome for the generalized adoption of AI in the pathology setting?
12	What ethical issues could arise from the use (and potential misuse) of AI in the pathology setting?

215 AI, artificial intelligence.

216

217 In Round 2, the panelists were asked to rate each of the questionnaire statements on a 7-point Likert  
 218 scale (from 1 to 7), with different scores designed to fit different categories of questions. For example, a  
 219 score of 1 might indicate “Very strongly disagree”, “Impossible” (with regard to likelihood of an event  
 220 occurring), “Disappear”(with regard to job number or availability), or “Not involved at all” (with regard to  
 221 degree of involvement in specific tasks), whereas a score of 7 might indicate “Very strongly agree”,  
 222 Certain”, “Dramatically increase”, or “Daily involvement”, depending on the question, with higher scores  
 223 generally representing a more favorable opinion toward the future role or impact of AI on Pathology  
 224 (table 3).

225

226 **Table 3.** Likert scales for the different sections (7-point)

Point Score	Agreement scale	Probability scale	Job number variation scale	Involvement scale
1	Very strongly disagree	Impossible	Disappear	Not involved at all
2	Strongly disagree	Very unlikely	Greatly decrease	Rarely involved
3	Disagree	Unlikely	Somewhat decrease	Somewhat involved
4	Neither agree nor disagree	Even chance / neutral	Remain the same	Sometimes involved



5	Agree	Likely	Somewhat increase	Often involved
6	Strongly agree	Very likely	Greatly increase	Routinely involved
7	Very strongly agree	Certain	Dramatically increase	Daily involved

227  
228

229 In Round 3, the panelists were asked to re-rate all statements which did not reach consensus during  
230 Round 2. Consensus on statements was defined, a priori, as having an interquartile range (IQR) of less  
231 than 1 ( $IQR \leq 1$ ) for ratings along the 7-point Likert scale.<sup>55,56</sup> During Round 3, the panelists were  
232 shown their Round 2 ratings on each statement, along with the median and IQR for the group as a  
233 whole, and finally given the option to change their previous ratings, if desired.

234

235 All questionnaires were completed via an online Google Form (Google Inc, Mountain View, CA, USA),  
236 with individualized links to the form e-mailed to each panelist. The survey participants remained  
237 anonymous to one another during all three Rounds, with each participant able to view only their own  
238 responses to each statement during Rounds 1 and 2, along with the anonymized group medians and  
239 IQRs during Round 3.

240

#### 241 *Statistical Analysis*

242 To examine whether any significant differences in panelist scores were present based on gender,  
243 practice location, pathology subspecialty, or years in practice, Wilcoxon rank-sum tests (two-tailed,  
244  $\alpha = 0.05$  significance criterion) were performed. All analyses were performed using Microsoft Excel  
245 (Microsoft Corporation, Redmond, WA, USA) and STATA v16 (StataCorp LLC, College Station, TX,  
246 USA).

247

## 248 **RESULTS**

### 249 *Survey Rounds*

250 The unstructured first Delphi round allowed the panelists relative freedom in expressing their individual  
251 thoughts on topics they felt were important or relevant to the future of AI in pathology over the next  
252 decade. This resulted in the generation of 180 summative statements spanning the following nine  
253 categories: 1) impact of AI on key performance indicators (KPIs), 2) impact of AI on the pathology

254 workforce, 3) impact of AI on pathologist tasks, 4) impact of AI on pathology technician tasks, 5)  
255 specific applications of AI in pathology, 6) role of pathology AI in integrated diagnostics, 7) pathology  
256 tasks likely to be fully automated by AI, 8) regulatory and legal aspects of AI integration, and 9) ethical  
257 aspects of AI integration.

258

259 One of the motivations behind using the Delphi method was its ability to achieve greater consensus (a  
260 reduction in variance across rounds, as measured by the IQR) among a limited number of expert  
261 panelists. After Round 2, responses to 48 of the 180 (26.7%) statements reached consensus ( $IQR \leq 1$ ).  
262 After Round 3, the panelists had reached consensus on 141 of the 180 (78.3%) statements. The mean  
263 and median Likert scores across the panelists for each of the 180 statements ranged from 3.04 to 6.83  
264 (mean), and from 3 to 7 (median), respectively. Tables 4 through 10 present the 100 statements  
265 (spread across seven general categories) that achieved high directional consensus (defined as  $IQR \leq$   
266 1, *and* both mean and median scores of either  $\leq 3$  or  $\geq 5$ ) among the expert panelists. For these 100  
267 statements, two-tailed Wilcoxon rank sum tests demonstrated no significant differences in Likert scores  
268 between the various panelist comparison groups (female vs. male, North American vs. non-North  
269 American, subspecialty informatics or computational/digital pathology vs. other subspecialty, and  $\leq 10$   
270 years vs.  $\geq 11$  years in practice) on 85 of the 100 statements. The remaining 15 statements are further  
271 discussed in the corresponding sections below, which summarize the most significant results of the  
272 survey according to topic/category

273

#### 274 *Impact of AI on Pathology Key Performance Indicators (KPIs)*

275 In general, there was agreement that AI would help improve laboratory KPIs, such as turnaround time,  
276 diagnostic accuracy, the detection rate for rare events (for example, small foci of primary or metastatic  
277 tumor), and quality of diagnostic reports (**table 4**). However, it was also anticipated that histopathologic  
278 analyses would become more quantitative, and that diagnostic reports would become more complex.  
279 There was also agreement that AI would lead to greater standardization of diagnostic and pre-analytical  
280 processes, such as tissue sectioning, staining techniques, and workflows. As a result of these  
281 anticipated improvements in KPIs, it was expected that there would be an increase in the satisfaction of  
282 referring physicians. A statement regarding the likelihood of the cost per case decreasing with the use  
283 of AI failed to reach consensus, although a majority of the experts predicted the cost per case would  
284 not decrease with medium term AI use (within the next 8-10 years). In addition, the panelists did not  
285 reach consensus on whether the number of second-opinion consultations would decrease as a result of  
286 AI adoption.

287

288 **Table 4.** Statements on which high directional consensus was reached regarding the impact of AI on  
289 pathology key performance indicators (KPIs)

<b>By 2030, due to the integration of AI in the pathology setting...</b>			
<i>Key performance indicator</i>	<i>Mean</i>	<i>Median</i>	<i>Result</i>
Standardization of pre-analytical processes (staining and slicing techniques) will increase	5.38	5	Agree
Diagnostic accuracy will increase	5.67	6	Strongly agree
Diagnosis and grading of tumors will be more standardized, bringing more objectivity to the diagnosis of certain entities that are currently subject to high interobserver variability	6.04	6	Strongly agree
Detection of rare events (small metastases, small tumor foci) will increase	5.88	6	Strongly agree
Analyses will be more quantitative	6.21	6	Strongly agree
Completeness of reports will increase	5.13	5	Agree
Complexity of reports will increase	5.13	5	Agree
Quality of reports will increase	5.38	5	Agree

290 AI, artificial intelligence.

291  
292

293 **Table 4** presents those statements regarding the impact of AI on pathology KPIs for which there was  
294 high directional consensus among the panelists. Overall, these results projected, by the year 2030,  
295 growth in computational pathology as a subspecialty with AI applications assisting pathologists in  
296 making diagnoses that are more accurate, standardized, objective, quantitative, and complete.

297

#### 298 *Impact of AI on the Pathology Workforce and Specific Tasks*

299 There was agreement that the number of jobs for pathologists, as well as administrative staff, would  
300 likely remain the same. However, a modest increase in the number of jobs for technicians and  
301 information technology (IT) professionals was expected. While the size of the overall pathology job  
302 market was not expected to vary greatly due to the adoption of AI, the types and frequencies of tasks  
303 performed by pathologists and pathology laboratory technicians were expected to change significantly.  
304 There was agreement that AI would facilitate subspecialization in pathology, with the number of  
305 pathologists specializing in computational pathology greatly increasing. Tables 5 and 6 present the  
306 expected impact of AI on the pathologist (**table 5**) and pathology laboratory technician (**table 6**)  
307 workforces and associated tasks.

308

309

310

311  
312

**Table 5.** Statements on which high directional consensus was reached regarding the impact of AI on pathologist workforce and tasks

<b>By 2030, due to the integration of AI in the pathology setting...</b>			
<i>Task</i>	<i>Mean</i>	<i>Median</i>	<i>Involvement/Agreement Level</i>
The number of jobs for IT staff will...	5.54	5	Somewhat increase
The number of specialized “computational” pathologists will greatly increase	5.75	6	Strongly agree
Pathologists will be more involved in diagnostic tumor boards	5.58	6	Strongly agree
Pathologists will be more involved in multidisciplinary conferences	5.63	6	Strongly agree
Pathologists will be more involved in research activities	5.42	5	Agree
Pathologists will be spending more time in the study of rare lesions	5.13	5	Agree
<b>By 2030, due to the integration of AI in the pathology setting, the degree of involvement of pathologists in these tasks will be...</b>			
Digital pathologic diagnosis without the use of physical glass slides	5.58	6	Routine
Interpretation of computationally derived measurements and evaluations	6.08	6	Routine
Collaboration with EHR teams regarding the use of laboratory data for a wide range of clinical decision support tools	5.25	5.5	Routine
Evaluating different kinds of AI software and deciding whether these are appropriate for their workflow	5.54	6	Routine
Validation and QA/QC of AI solutions	5.63	6	Routine
Validation and QA/QC of AI-rendered diagnoses	5.88	6	Routine
Defining new categories of patients, based on new data made available through AI	5.04	5	Often

313 AI, artificial intelligence; IT, information technology; EHR, electronic health record; QA/QC, quality  
314 assurance/quality control.

315  
316  
317  
318

**Table 6.** Statements on which high directional consensus was reached regarding the impact of AI on pathology lab technician workforce and tasks

<b>By 2030, due to the integration of AI in the pathology setting, the degree of involvement of pathology laboratory technicians in these tasks will be...</b>			
<i>Task</i>	<i>Mean</i>	<i>Median</i>	<i>Involvement Level</i>
Operation of digital slide scanners, digitization, and image management	6.25	7	Daily
QA/QC of digitized images	6.08	6.5	Daily
Digital pathology support for pathologists and other users, such as device calibration	5.88	6	Routine
Assessing histology consistency, i.e., re-addressing SOPs to make slides and corresponding images more suitable for AI (more consistent tissue and staining quality)	5.83	6	Routine

Validation and QA/QC of AI-rendered diagnoses	5.17	5	Often
---	------	---	-------

319 AI, artificial intelligence; SOP, standard operating procedure; QA/QC, quality assurance/quality control.

320  
321

322 There was agreement that, by 2030, pathologists would be routinely involved in new tasks related to  
323 the incorporation of AI into their workflows, such as interpreting diagnostic outputs from AI algorithms,  
324 evaluating AI software, and performing validation and quality assurance/quality control (QA/QC) for AI  
325 solutions and AI-rendered diagnoses. There was also agreement pathologists would be directly  
326 participating in the design and development of AI solutions and, based on the availability of new data  
327 generated by AI, they would also be contributing to the definition of new categories of patients. As a  
328 result of AI adoption, pathologists were also expected to be more involved in ancillary activities, such as  
329 research and participation in multidisciplinary conferences and tumor boards. The panelists also agreed  
330 pathologists would sometimes be more involved in meeting directly with patients, including more  
331 frequent inclusion in patient treatment decision-making.

332

333 Compared to the panelists who had been in practice for 11 years or longer, those in practice for 10 or  
334 fewer years (7 panelists) more strongly agreed that digital pathologic diagnosis without the use of  
335 physical glass slides would be routine by 2030 ( $p = 0.041$ ), with a median score of 7 (compared with a  
336 median score of 6, for those with 11 or more years of practice) and mean score of 6.43 (compared to a  
337 mean score of 5.23, for those with 11 or more years of practice). The same group also more strongly  
338 agreed that interpretation of computationally derived measurements and evaluations would be routine  
339 ( $p = 0.048$ ), with a median score of 7 (compared with a median score of 6, for those with 11 or more  
340 years of practice) and mean score of 6.71 (compared to a mean score of 5.82, for those with 11 or  
341 more years of practice).

342

343 The work of pathology technicians was also expected to undergo major changes as a result of AI  
344 adoption (**table 6**). Technicians would be routinely involved in tasks related to new digital and  
345 computational workflows, such as scanner operation, device calibration, and QA/QC of digitized  
346 images. There was no consensus, however, as to whether technicians would be directly participating in  
347 AI-assisted diagnosis, although a slight majority of the panelists surveyed thought this would be the  
348 case.

349

350 The panelists subspecializing in informatics or computational/digital pathology (8 panelists) more  
351 strongly felt that pathology laboratory technicians would routinely be providing digital pathology support  
352 for pathologists and other users (for example, by performing device calibration and other tasks) ( $p =$   
353 0.005), with a median score of 7 and a mean score of 6.63 (as compared to a median of 6 and a mean

354 of 5.50 for those not subspecializing in informatics or computational/digital pathology). Similarly, this  
355 group also felt more strongly that pathology laboratory technicians would be routinely involved in  
356 assessing and improving the consistency of histologic tissue preparation and staining to make images  
357 more suitable for AI ( $p = 0.049$ ), with a mean score of 6.25 (as compared to a mean of 5.63, with the  
358 same median of 6, for those not subspecializing in informatics or computational/digital pathology).  
359

### 360 *Applications of AI to Pathology and Integrated Diagnostics*

361 AI was expected to positively impact many aspects of the pathology workflow. The panelists proposed  
362 several specific applications they thought would likely be in routine use in pathology laboratories by the  
363 year 2030 (**table 7**). Regarding the analysis and interpretation of histologic images, routine applications  
364 included algorithms for the identification of hotspot areas (for example, during mitotic counts), detection  
365 of microorganisms (such as acid-fast bacilli and *Helicobacter pylori*) and cancer, and assistance with  
366 tumor grading. The panelists were also certain AI would be in routine use for the automated  
367 quantification of immunohistochemical (IHC) and immunofluorescent (IF) biomarker stains, such as Ki-  
368 67, estrogen receptor (ER), progesterone receptor (PgR), and programmed cell death ligand 1 (PD-L1),  
369 as well as the counting of mitotic figures and lymphocytes on hematoxylin and eosin (H&E) stained  
370 tissue, and the identification of lymph node metastases and, in particular, micrometastases.

371

372 **Table 7.** Statements on which high directional consensus was reached regarding AI applications in  
373 pathology

<b>By 2030, the probability of these AI tools being routinely used in pathology labs is...</b>			
<i>AI application</i>	<i>Mean</i>	<i>Median</i>	<i>Likelihood</i>
Identification of micrometastases	6.17	6.5	Certain
Detection of lymph node metastases	6.33	7	Certain
Quantification of IHC or IF stains, such as Ki-67, ER, PgR, PD-L1	6.67	7	Certain
Quantification of number of mitoses in H&E-stained images	6.33	6.5	Certain
Counting lymphocytes	6.42	6.5	Certain
Automated ordering of IHC for specific applications / assisting with selection of immunohistochemical stains needed	5.46	6	Very likely
Automated QA/QC of IHC positive and negative controls	5.75	6	Very likely
Proposing specific IHC or other molecular methods to solve a specific diagnostic problem	5.17	5.5	Very likely
Prioritization of cases (such as cases with neoplasia and infectious organisms in immunosuppressed patients)	5.50	6	Very likely
Quality control of whole-slide images (scanning process), and detection of poor-quality slides (tissue folds, poor staining)	6.13	6	Very likely
Quality improvement of whole-slide images	6.00	6	Very likely



Pre-selecting regions of interest suspicious for cancer for pathologists to view	6.29	6	Very likely
Identification of hotspot areas	6.25	6	Very likely
Detection of microorganisms (AFB, <i>H. pylori</i> )	6.17	6	Very likely
Assisting with tumor grading	6.21	6	Very likely
Quantification of eosinophils in eosinophilic esophagitis	6.13	6	Very likely
Quantitation of features (e.g., fibrosis in various organs, liver steatosis, etc.)	6.29	6	Very likely
Marking of perineural invasion, lymphovascular invasion	5.79	6	Very likely
Automated measurements (e.g., of tumor areas)	6.21	6	Very likely
Ensuring all diagnostically relevant areas on the slide are viewed prior to report finalization	5.42	6	Very likely
Mandatory second reads when the pathologist diagnosis does not match the potential AI diagnosis (within a predefined range/percentage; e.g., if the AI tool detects potential tumor on a biopsy but the pathologist reads the biopsy as no evidence of tumor)	5.79	6	Very likely
Standardization of pathology reports	5.88	6	Very likely
AI-assisted laboratory workflow management, including workload assignments to pathologists, residents, and technicians	5.33	5	Likely
Detection of signet ring-cell cancer	5.29	5	Likely
Pre-selection of potentially cancer-positive samples for pathologist's review, while the bulk of clearly negative samples can be automatically processed	5.13	5	Likely
Triaging of cases to the most appropriate pathologist at the earliest possible time	5.08	5	Likely
Providing a set of differential diagnoses on difficult cases	5.13	5	Likely
Proposing specific additional tests for solving a diagnostic problem (e.g., AI algorithm suggesting STAT6 immunostaining on a spindle cell neoplasm of the pleura)	5.17	5	Likely
Import of contextually-related data on a case for quick review by the pathologist during diagnostic slide review	5.21	5	Likely
Pre-populating relevant report details from the medical record/gross description	5.29	5	Likely
Selection of the appropriate synoptic report based on prior pathology findings, including the current case gross report	5.38	5	Likely
Pre-populating reports based on AI interpretation of images	5.13	5	Likely
Finding the source of contaminants	5.17	5	Likely

374 AI, artificial intelligence; IHC, immunohistochemistry; IF, immunofluorescence; ER, estrogen receptor;  
 375 PgR, progesterone receptor; PD-L1, programmed cell death ligand 1; H&E, hematoxylin and eosin;  
 376 QA/QC, quality assurance/quality control; AFB, acid-fast *Bacillus*; *H. pylori*, *Helicobacter pylori*; STAT6,  
 377 signal transducer and activator of transcription 6.  
 378  
 379

380 Tasks which are currently performed manually, but which were expected to be replaced by AI  
 381 automation by the year 2030, included the provision of size measurements (e.g., tumors) and the



382 detection of perineural and lymphovascular invasion in malignancies. In addition, it was expected that  
383 AI-based computational/virtual staining would replace the need for multiplex histochemistry and IHC/IF.

384

385 Within a decade, AI was expected to increase diagnostic efficiency by prioritizing regions of interest  
386 suspicious for cancer involvement for pathologists to review first, pre-populating relevant diagnostic  
387 report fields using data extracted from the medical record and/or gross description, and pre-populating  
388 diagnostic reports based on AI interpretation of whole-slide images. In addition, AI was expected to  
389 assist pathologists with making more accurate diagnoses by importing contextually relevant clinical  
390 history and other data related to a case for quick review by the pathologist during case sign-out,  
391 providing a set of differential diagnoses, and prompting second reads on cases where there was a  
392 discrepancy between the pathologist diagnosis and the diagnosis rendered by the AI algorithm.

393

394 The panel also foresaw a significant impact of AI on other aspects of the laboratory workflow. Routine  
395 AI-assisted prioritization of cases for pathologist review, suggestions for ancillary stains to be  
396 performed, and automated ordering of additional stains were thought to be very likely by 2030 (**table 7**).  
397 In terms of differences in opinion between the various panelist subgroups, those subspecializing in  
398 informatics or computational/digital pathology less strongly believed that AI would routinely be used for  
399 the quantification of eosinophils in eosinophilic esophagitis ( $p = 0.049$ ), with a mean score of 5.75, as  
400 compared to a mean of 6.31 (with the same median of 6), for the other subspecialists.

401

402 AI was expected to foster the integration of pathology with other diagnostic modalities, such as  
403 radiology and genomics, by: 1) identifying histologic regions of interest to be sampled for genomic  
404 testing; 2) correlating morphologic and genomic information to help interpret genetic aberration; 3)  
405 comparing tumor extent on histology slides and radiologic images; and 4) interpreting tumor treatment  
406 response in radiologic images, based on pathology data. Multimodal-AI was also expected to enable  
407 the combination of diverse types of diagnostic data (gross/macroscopic, microscopic, radiologic, and  
408 genomic) in a single interface, and to facilitate the use of integrated diagnostic reports for certain  
409 diseases, such as prostate cancer (**table 8**). Consequently, it was felt AI-powered integrated  
410 diagnostics would likely lead to significant advances in the personalization of healthcare by creating  
411 new categories of patients based on differential risk stratification (prognostic) roadmaps and prediction  
412 of clinical outcomes.

413

414 **Table 8.** Statements on which high directional consensus was reached regarding the role of AI in  
415 integrated diagnostics

<b>By 2030, the probability of these integrated diagnostic applications being used routinely is...</b>			
<i>AI application</i>	<i>Mean</i>	<i>Median</i>	<i>Likelihood</i>

Identification of histologic regions to be sampled for genomic testing	5.38	5	Likely
Prediction of biomarker status and clinical outcomes for personalized medicine, based on integrated diagnostics	5.08	5	Likely
Selection of patients with prostate cancer for active surveillance versus radiotherapy/surgery, based on integration of pathology and radiology data	5.00	5	Likely
Creation of new categories of patients by integrating all “big data” from pathology, clinical lab, radiology, and genomics	5.04	5	Likely
Building risk stratification (prognostic) roadmaps for individual patients based on input from histology, radiology, and genomics	5.13	5	Likely
Use of integrated reports for select conditions, e.g., prostate cancer	5.33	5	Likely

416 AI, artificial intelligence.

417

418

419 The panelists with greater practice experience ( $\geq 11$  years) more strongly believed the integration of  
 420 pathology and radiology data would routinely be used to select patients for active surveillance versus  
 421 radiotherapy/surgery in prostate cancer ( $p = 0.044$ ; equal medians of 5 but mean of 5.29 versus 4.29  
 422 for those with  $\geq 11$  years and  $\leq 10$  years of practice experience, respectively). The panelists with more  
 423 practice experience more strongly believed that AI would routinely be used to build risk stratification  
 424 (prognostic) roadmaps for patients based on histologic, radiologic, and genomic input data ( $p = 0.020$ ;  
 425 equal medians of 5, means of 5.41 versus 4.43 for those with  $\geq 11$  years and  $\leq 10$  years of practice  
 426 experience, respectively).

427

428 The panelists felt it was likely that, by 2030, AI would not simply assist with, but would fully replace,  
 429 pathologists on several manually-performed tasks. Among these were stain selection; measurement  
 430 tasks; prioritization and triage of cases; screening for microorganisms; colorectal polyp, cervical  
 431 cytology, and lymph node screening; and grading of breast and colorectal cancers (**table 9**). Assigning  
 432 work to pathologists, trainees, and technicians, as well as triaging cases to the appropriate pathologist,  
 433 were also deemed likely to be fully automated by AI.

434

435 **Table 9.** Statements on which high directional consensus was reached regarding pathology tasks  
 436 expected to be fully automated by 2030

<b>By 2030, the probability of these tasks being fully delegated to AI in pathology labs is...</b>			
<i>Task</i>	<i>Mean</i>	<i>Median</i>	<i>Likelihood</i>
Verification of positive and negative controls for IHC	5.71	6	Very likely
Prioritization of cases	5.54	6	Very likely
Triage of cases to appropriate pathologists	5.46	6	Very likely

Contextual data lookup on patients from the EHR relevant to the pathology case being reviewed	5.25	6	Very likely
Slide QC (e.g., detection of tissue folds and tears, stain quality evaluation, etc.)	5.88	6	Very likely
Screening for microorganisms, such as AFB and <i>H. pylori</i>	5.96	6	Very likely
Screening of colorectal polyps	5.58	6	Very likely
Cervical cytology screening	6.21	6	Very likely
Screening lymph nodes for metastases	5.83	6	Very likely
Measurement tasks	6.17	6	Very likely
Quantification of IHC or IF stains, such as Ki-67, ER, PgR, PD-L1	6.29	6	Very likely
Quantification of mitotic count on H&E-stained images	6.08	6	Very likely
Bone marrow differential counts	5.54	6	Very likely
MIB-1 scoring	6.04	6	Very likely
Assessing extent of liver steatosis and fibrosis	5.54	6	Very likely
Screening of tissues with a cancer diagnosis to select regions for tissue coring or macroscopic dissection	5.08	5	Likely
Slide screening for regions of interest	5.13	5	Likely
Grading of breast cancer	5.42	5	Likely
Grading of colorectal cancer	5.33	5	Likely

437 AI, artificial intelligence; IHC, immunohistochemistry; EHR, electronic health record; QC, quality control;  
 438 AFB, acid-fast *Bacillus*; *H. pylori*, *Helicobacter pylori*; IF, immunofluorescence; ER, estrogen receptor;  
 439 PgR, progesterone receptor; PD-L1, programmed cell death ligand 1; H&E, hematoxylin and eosin.  
 440  
 441

442 The panelists practicing outside of North America (11 panelists) thought it more likely that colorectal  
 443 polyp screening would be fully delegated to AI by the year 2030 ( $p = 0.047$ ; mean = 6 and median = 6  
 444 for non-North American panelists, versus mean = 5.23 and median = 5 for North American panelists).  
 445 Those with more practice experience ( $\geq 11$  years) thought it more likely that mitotic counts on H&E-  
 446 stained images would be fully delegated to AI ( $p = 0.036$ ; equal medians of 6 but mean of 6.29 versus  
 447 5.57 for those with  $\geq 11$  years and  $\leq 10$  years of practice experience, respectively).  
 448

#### 449 *Regulatory and Ethical Aspects of AI Integration in Pathology*

450 The panelists foresaw significant regulatory and ethical challenges posed by the integration of AI in  
 451 pathology (**table 10**). While some panelists initially suggested such issues might not pose a challenge  
 452 to the application of AI in pathology, since the pathologist (or another physician) always takes the  
 453 ultimate responsibility for the diagnostic, therapeutic or prognostic use of AI, the final consensus  
 454 opinion overruled that initial suggestion. In principle, the panel agreed that both primary diagnostic and  
 455 secondary (e.g., advisory/assistive) algorithms would have to meet strict regulatory requirements.  
 456 There was agreement that regulatory bodies would create new guidelines addressing the integration of

457 AI into pathology, which would provide specific validation procedures and simplify regulatory pathways  
 458 for AI tools, although regulatory clearance of AI software would still be a lengthy and costly process.  
 459

460 **Table 10.** Statements on which high directional consensus was reached regarding regulatory and  
 461 ethical aspects

<b>By 2030, regarding the integration of AI in pathology...</b>			
<i>Aspect</i>	<i>Mean</i>	<i>Median</i>	<i>Likelihood</i>
A set of new guidelines will be developed, specifically addressing the integration of AI in pathology	6.63	7	Very strongly agree
Specific validation procedures for different types of AI tools will be defined by regulatory bodies	6.46	7	Very strongly agree
The introduction of AI-based diagnostic modalities will require regulatory supervision, both related to the quality of the rendered diagnosis and the ultimate destination of the diagnostic information	6.83	7	Very strongly agree
As long as AI is used as a supportive method, ethical issues will be minor. However, when AI takes over tasks from the pathologist, i.e., making a diagnosis without human oversight, it will face major ethical challenges.	6.58	7	Very strongly agree
Pathologists will still be legally responsible for diagnoses made with the help of AI	6.25	7	Very strongly agree
Meeting regulatory requirements for most AI applications will be a lengthy and costly process, as it will involve large-scale prospective studies	5.46	5,5	Strongly agree
Definition of end-points for validation clinical studies will be a common problem	5.50	6	Strongly agree
Post-marketing surveillance will pose important challenges, due to algorithm drift	5.50	6	Strongly agree
Regulatory approval of AI tools used for definitive (primary) diagnosis will be very strict, but AI used for advisory purposes (secondary) will also have to meet strict regulatory conditions	6.04	6	Strongly agree
CLIA regulations and clarification surrounding the use of laboratory data within pathology and laboratory processes versus outside of the laboratory will be reviewed and updated	5.63	6	Strongly agree
Governments will actively promote innovation in the areas of AI and medicine, fostering the advancement of AI in pathology	5.88	6	Strongly agree
Legal disputes will often arise regarding who should assume liability (pathologist, institution, developer, commercial vendor...) for diagnostic errors induced by AI	5.67	6	Strongly agree
AI and technology will be included in the educational curricula for medical students, pathologists, and analysts to help them deal with this rapidly evolving method of support and its ethical implications	5.88	6	Strongly agree
Hurried pathologists will often take “shortcuts” by accepting AI interpretations without verification	5.08	5	Agree

Potentially-biased algorithms due to lack of demographic diversity in training datasets will lead to diagnostic errors	5.13	5	Agree
Data inferences that may impact on patient anonymity will lead to ethical issues	5.17	5	Agree

462 AI, artificial intelligence; CLIA, Clinical Laboratory Improvement Amendments.

463

464 There was also agreement that the regulatory approval of adaptive algorithms, which continuously  
465 evolve in response to new input data, would be possible, but that algorithm drift would pose important  
466 challenges that would need to be tackled by close post-market surveillance. It was also anticipated that  
467 legal disputes would arise regarding who should assume liability for diagnostic errors induced by AI,  
468 with pathologists still being held legally responsible for AI-assisted diagnosis.

469

470 With regard to differences in opinion between the various panelist subgroups, the North American  
471 panelists more strongly believed that CLIA regulations and clarification surrounding the use of  
472 laboratory data within pathology, as well as laboratory processes, would need to be reviewed and  
473 updated ( $p = 0.031$ ; median = 6 vs. median = 5 and mean = 6 vs. mean = 5.18 for North American vs.  
474 other panelists, respectively). Those subspecialized in informatics or computational/digital pathology  
475 less strongly believed that legal disputes would often arise regarding who should assume liability for  
476 diagnostic errors induced by AI ( $p = 0.018$ ; mean = 4.88 and median = 5), compared to those not  
477 subspecialized in those areas (mean = 6.06 and median = 6).

478

479 Overall, the panel acknowledged there would be major ethical issues arising from the full delegation of  
480 tasks to AI algorithms, believing it likely that hurried pathologists would often accept AI interpretations  
481 without sufficient verification. On the other hand, there was disagreement between the panelists  
482 regarding whether the black box nature of AI algorithms would cause pathologists to often make  
483 diagnoses without enough clinical explainability. The panelists who had been in practice fewer years ( $\leq$   
484 10 years) more strongly believed that ethical issues would result from data inferences which might  
485 compromise patient anonymity ( $p = 0.004$ ; mean = 6 and median = 6), compared to those in practice  $\geq$   
486 11 years (mean = 4.82 and median = 5).

487

488 Finally, there was general consensus that ethical issues were expected to arise due to: 1) risk for  
489 diagnostic error resulting from the use of potentially biased algorithms trained on datasets lacking  
490 sufficient demographic diversity; and 2) the lack of proper informed consent when using patient data  
491 (which the panel agreed would become a common practice). Nevertheless, the panelists expected  
492 official regulatory bodies would do their part to overcome the aforementioned ethical and legal  
493 challenges, and funding bodies would actively promote innovation in AI and medicine, thereby fostering

494 the advancement of AI in pathology. It was also anticipated AI would be integrated into both medical  
495 school and continuing medical education curricula for pathologists in current practice, in order to help  
496 them adapt to this rapidly evolving area and its associated legal and ethical implications.

497

## 498 **DISCUSSION**

499 From this first ever consensus study of a panel of 24 international experts with first-hand experience  
500 working in the field of computational pathology and AI (almost all of whom are also pathologists in  
501 active clinical practice), we obtained specific insight into consistently agreed-upon opportunities and  
502 challenges, as well as perspectives and predictions, relevant to the expected role of AI in pathology  
503 over the next decade. Our panel was composed of experts of both genders, practicing in 11 different  
504 countries, specializing in a wide range of pathology subspecialties, and with a wide range of years in  
505 practice (with all panelists having attending pathologist/faculty status). Despite this diversity in the  
506 expert panel, the panelists were able to reach consensus agreement on 140 (78.3%) of the 180 items  
507 surveyed.

508

509 There was particularly strong consensus AI would improve the KPI of diagnostic accuracy, at least  
510 partially by assisting with the detection of rare events (such as small tumor foci and metastases),  
511 standardizing the diagnosis and grading of tumors, and making histopathologic analyses more  
512 quantitative. There was also particularly strong consensus that the number of specialized computational  
513 pathologists would greatly increase, and that pathologists would be more involved in diagnostic tumor  
514 boards and multidisciplinary conferences as a result of AI integration. Significant changes in the types  
515 of tasks routinely performed by a pathology laboratory technician were also expected. It was projected  
516 that laboratory technicians would be operating digital slide scanners and performing digital image  
517 management and QA/QC daily.

518

519 It was felt to be *almost certain* that specific pathology AI applications would be in routine use by 2030 –  
520 namely, algorithms for the identification of lymph node macro- and micro- metastases, IHC/IF stain  
521 quantification (including Ki-67, ER, PgR, and PD-L1), mitosis quantification, and lymphocyte  
522 quantification. It was also felt to be *very likely* that algorithms would be in routine use for: 1) specific  
523 pre-analytical tasks, such as automated QA/QC of histologic preparation, WSI quality, and IHC  
524 controls, automated suggestion or ordering of ancillary stains and molecular tests, and automated case  
525 prioritization; 2) specific analytical tasks, such as pre-selection of cancer regions of interest and hotspot  
526 areas, microorganism detection, tumor grading, eosinophil and feature quantification, tumor area



527 measurement, identification of lymphovascular and perineural invasion, diagnostic report  
528 standardization, and ensuring that all diagnostically-relevant areas in a WSI are viewed prior to report  
529 finalization; and (3) specific post-analytical tasks, such as enforcement of mandatory second reads  
530 when there is a significant discrepancy between the pathologist-rendered and AI-rendered diagnoses.  
531 The panelists felt it *very likely* that many of the preceding tasks, along with colorectal polyp and cervical  
532 cytology screening, case triage and assignment to pathologists, and contextual electronic  
533 health/medical records data lookup, would no longer be performed by pathologists in the year 2030, as  
534 they will have been *fully delegated* to AI. These predictions are consistent with the relatively high  
535 representation of many available applications in the existing pathology AI research literature.<sup>29,31,41,43,57–</sup>

536 <sup>63</sup>

537  
538 At the same time, it is interesting to note that many of the applications projected to be in routine use  
539 within the next decade address basic or mundane tasks already being performed by pathologists,  
540 rather than advanced or "aspirational" tasks pathologists do not currently perform (such as prediction of  
541 molecular biomarker status or clinical outcomes directly from morphologic features on H&E-stained  
542 slides). The relative projected likelihoods of these two dominant categories of AI applications ("basic"  
543 versus "aspirational") being in routine use by 2030 seems, in many ways, contrary to the relative  
544 degree of attention paid to these categories by the research community and industry stakeholders.  
545 <sup>35,41,64–66</sup> For example, in a recent survey from 2021,<sup>67</sup> 75 computational pathology domain experts from  
546 academia and industry (48% with medical and 52% with non-medical backgrounds) were asked to  
547 provide their subjective rankings regarding the degree of interest, importance, and/or promise of 12  
548 solid tumor-specific pathology AI applications. Among the applications surveyed, those falling within the  
549 advanced/aspirational categories were consistently rated the most highly, while those falling within the  
550 more basic/mundane categories (such as QA/QC, tumor grading, and subtyping) were rated the lowest,  
551 with the most highly-rated application being prediction of treatment response directly from H&E images,  
552 followed by prediction of genetic mutations, gene expression, and survival directly from H&E images,  
553 respectively. Although "degree of interest/importance/promise" is not exactly equivalent to the  
554 "likelihood of routine near-term adoption", the somewhat discrepant findings between the two surveys,  
555 each of which targeted different participant populations, suggests that those with non-medical and/or  
556 industry backgrounds (who collectively formed the majority of participants in the cited study) might be  
557 more optimistic about the near-term role and importance of advanced/"aspirational" AI applications in  
558 pathology than pathologists with first-hand experience working in the areas of computational  
559 pathology/AI, who tend to have a more practical perspective regarding those AI applications likely to  
560 enjoy widespread adoption in the near to medium term. It was unclear from our study why more  
561 advanced/"aspirational" AI tools were not predicted to be in routine use within the next decade.



562 Perhaps, it was felt that such tools, though interesting from a research standpoint, would never reach  
563 the level of performance required for clinical adoption. Or, in order to have a sufficient level of  
564 performance for these tools, the fundamental AI infrastructure addressing the “basic” tasks would have  
565 to be completed first, paving the way for full diagnostic AI algorithm clinical validation and regulatory  
566 clearance. It remains for future studies to explore the reasons underpinning the results observed in this  
567 (and other) surveys regarding clinical AI.

568

569 Only a few other studies have sought to survey the opinions of various stakeholders regarding AI in  
570 pathology. In a 2018 survey of 363 practicing pathologists and 124 pathology trainees from 54  
571 countries (46% female, 56% practicing in the United States, Canada, or the United Kingdom, and 43%  
572 in practice for  $\leq 10$  years) on general perspectives regarding the integration of AI into diagnostic  
573 pathology, 81% of respondents predicted that AI would be integrated into pathology workflows within  
574 the next 5–10 years.<sup>34</sup> In the same survey, 38% of respondents felt that AI would have no impact on  
575 pathologist employability, 42% felt that it would create new positions and improve employment  
576 prospects, and 20% were either concerned or extremely concerned that AI would displace them from  
577 their jobs. Approximately 72% of the respondents also felt that AI tools could increase or dramatically  
578 increase diagnostic efficiency, with the remaining 28% being unsure of AI's impact on efficiency, or of  
579 the opinion that AI would have either no impact or a negative impact on efficiency. In contrast to the  
580 more heterogeneous respondent demographic in that survey, the participants in our survey were  
581 composed almost exclusively of practicing pathologists with experience in computational pathology/AI.  
582 Although the consensus perspectives from our survey were more optimistic regarding the impact of AI  
583 on the pathologist workforce, there was similar reservation regarding whether AI integration would truly  
584 lead to increased efficiency, in terms of cost per case (one of the KPI's which failed to reach consensus  
585 in our study) and turnaround time per case (which failed to reach high directional consensus).

586

587 Finally, it is worth noting some of the areas where there was either a lack of consensus among the  
588 panelists, or consensus toward a less optimistic perspective on the topic in question. There was a lack  
589 of consensus regarding whether AI would reduce the cost per case or the number of cases requiring  
590 pathologist review (after automated AI-based filtering of negative/normal cases), and whether it would  
591 increase patient satisfaction. There was also a lack of consensus regarding many regulatory aspects  
592 related to AI integration. For example, the panelists were uncertain whether it would become possible in  
593 the near future for approved developers to circumvent the requirement for individual approval of each  
594 new application, or whether legal and administrative barriers would be overcome regarding the use of  
595 de-identified images for research and education. There was general agreement that regulatory issues  
596 would still pose a challenge to the use of AI, even when the pathologist or another physician was the

597 final decision-maker regarding diagnosis, prognostication, or treatment. There were differences of  
598 opinion surrounding several ethical aspects of AI integration, including whether AI outputs used for  
599 clinical decision-making would always need to be manually reviewed by a pathologist, or whether other  
600 healthcare professionals would start using AI tools to diagnose cases without the aid of a pathologist.  
601 There was uncertainty around whether the “black box” nature of many AI tools would cause  
602 pathologists to make diagnoses without enough clinical explainability, and a lack of consensus  
603 regarding whether pathologists would occasionally make diagnoses contrary to their own judgment  
604 because of AI software recommendations. There was also no consensus on whether AI would lead to  
605 de-skilling of pathologists (a subject which remains controversial within the pathology community<sup>34</sup>), or  
606 whether it would be possible to ensure that pathologists took full responsibility for double-checking and  
607 confirming AI-rendered diagnoses. Due to the current AI “translation gap” in pathology, there have been  
608 either no, or only a limited number of, studies evaluating the impact of AI tools on pathologist  
609 behavior,<sup>25,26,59,68–71</sup> laboratory cost expenditures, medicolegal liability, or patient satisfaction. Therefore,  
610 the current lack of consensus among the panelists regarding the preceding topics is understandable  
611 and expected to be resolved as (1) more AI tools reach maturity and come to be evaluated in  
612 prospective clinical settings, and (2) more consideration is directed toward ensuring that AI models are  
613 integrated into pathology workflows in a manner that maximizes accuracy, time and cost efficiency,  
614 safety, transparency, accountability, and positive impact on patient outcomes.<sup>8,9,15,49,72</sup>

615  
616 Our study was subject to several limitations. Given the voluntary nature of participation and the  
617 substantial time commitment required to complete all three Delphi rounds, not all experts who were  
618 initially invited agreed to participate in the study, introducing the possibility of non-response bias. In  
619 addition, the proportion of female participants (16.7%) was much lower than the proportion of male  
620 participants. Although out of the 39 candidates originally invited to participate in this study 15 (38.9%)  
621 were women, possibly reflecting a relative underrepresentation of women in the pathology informatics  
622 and more specifically, the computational pathology/AI space, finally only four completed our survey.  
623 Only one of the participants was a cytopathologist (who also subspecialized in other areas of anatomic  
624 pathology), which may reflect the current underrepresentation of this subspecialty in computational  
625 pathology/AI due to the challenges of generating and storing z-stacked WSIs (which may resolve with  
626 the introduction of dedicated cytology whole-slide scanners in the near future).<sup>42</sup> Also, as most of the  
627 participants were practicing in North America and Europe, the results of this study may reflect a  
628 predominantly North American/European perspective that differs from the perspectives of those  
629 practicing in other parts of the world. Lastly, as our study was targeted toward a specific respondent  
630 demographic, individuals from other stakeholder groups (such as pathology trainees, pathologists with  
631 little or no experience in computational pathology/AI, pathology laboratory technicians, computer

632 scientists and others working in the computational pathology/AI space with non-medical backgrounds,  
633 physicians in other specialties, and patients) were not represented in our results. We anticipate all  
634 above issues to be sufficiently addressed in forthcoming studies, and that our survey, with its freely-  
635 available data collection forms, may serve as a model study for independent validation and extension.

636

637 We hope the results of this first systematic consensus study have provided a detailed vision of what  
638 pathology might look like in the year 2030, from the point of view of those with first-hand experience  
639 developing and evaluating clinical AI tools. Furthermore, we feel this study lays the groundwork for  
640 future follow-up studies in 3-5 years' and 10 years' time, assessing the evolution of expectations and  
641 challenges as the field of computational pathology progresses. Clearly, AI is expected to have a deep  
642 impact on the specialty of pathology, with several pathology AI applications anticipated to be in routine  
643 use by 2030, including some that will fully replace pathologists on specific tasks. The results of our  
644 study provide detailed insight into the current challenges, expectations, and perspectives surrounding  
645 the near to medium term role of AI in pathology, including timely and relevant information regarding  
646 how pathology care might be delivered in the future, assuming all regulatory and ethical questions are  
647 addressed.<sup>48,73</sup> We expect these findings will be of broad interest to a wide variety of stakeholders,  
648 including pathologists, pathology trainees and laboratory technicians, hospital administrators,  
649 researchers in academia, industry, and government, patients, professional societies, and regulatory  
650 bodies.

651

652

## 653 REFERENCES

654

- 655 1. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat*  
656 *Med*. 2019;**25**(1):44–56. doi: 10.1038/s41591-018-0300-7, PMID 30617339.
- 657 2. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare [internet].  
658 *Nat Med*. 2019;**25**(1):24–9. doi: 10.1038/s41591-018-0316-z, PMID 30617335.
- 659 3. Meskó B, Görög M. A short guide for medical professionals in the era of artificial intelligence.  
660 *NPJ Digit Med*. 2020;**3**:126. doi: 10.1038/s41746-020-00333-z, PMID 33043150.
- 661 4. Acs B, Rantalainen M, Hartman J. Artificial intelligence as the next step towards precision  
662 pathology. *J Intern Med*. 2020;**288**(1):62–81. doi: 10.1111/joim.13030, PMID 32128929.
- 663 5. Berbís MA, Aneiros-Fernández J, Mendoza Olivares FJM, Nava E, Luna A. Role of artificial  
664 intelligence in multidisciplinary imaging diagnosis of gastrointestinal diseases [internet]. *World J*  
665 *Gastroenterol*. Jul 21, 2021;**27**(27):4395–412. doi: 10.3748/wjg.v27.i27.4395, PMID 34366612.
- 666 6. Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. *Nat Med*.  
667 2022;**28**(1):31–8. doi: 10.1038/s41591-021-01614-0, PMID 35058619.

672

673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724

7. Abels E, Pantanowitz L, Aeffner F, et al. Computational pathology definitions, best practices, and recommendations for regulatory guidance: a white paper from the Digital Pathology Association. *J Pathol.* 2019;**249**(3):286–94. doi: 10.1002/path.5331, PMID 31355445.
8. Müller H, Holzinger A, Plass M, Brcic L, Stumptner C, Zatloukal K. Explainability and causability for artificial intelligence-supported medical image analysis in the context of the European in vitro diagnostic regulation. *New Biotechnol.* 2022;**70**:67–72. doi: 10.1016/j.nbt.2022.05.002, PMID 35526802.
9. McGenity C, Treanor D. Guidelines for clinical trials using artificial intelligence – SPIRIT-AI and CONSORT-AI. *J Pathol.* 2021;**253**(1):14–6. doi: 10.1002/path.5565, PMID 33016344.
10. FDA. Artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD) action plan. p. 1–7; Jan 12, 2021 [cited Jun 7, 2022]. Available from: <https://www.fda.gov/media/145022/download>.
11. FDA authorizes software that can help identify prostate cancer; Sep 21, 2021. FDA news release [cited Jun 7, 2022]. Available from: <https://www.fda.gov/news-events/press-announcements/fda-authorizes-software-can-help-identify-prostate-cancer>.
12. Das R. Five technologies that will disrupt healthcare by 2020. *Forbes* [cited Jun 7, 2022]. Available from: <https://www.forbes.com/sites/reenitadas/2016/03/30/top-5-technologies-disrupting-healthcare-by-2020/?sh=5b175d246826>; Mar 30, 2016.
13. Khosla V. Technology will replace 80% of what doctors do. *Fortune* [cited Jun 7, 2022]. Available from: <https://fortune.com/2012/12/04/technology-will-replace-80-of-what-doctors-do/>; Dec 4, 2012.
14. Longoni C, Morewedge CK. AI can outperform doctors. So why don't patients trust it? *Harv Bus Rev.* Oct 30, 2019.
15. Jackson BR, Ye Y, Crawford JM, et al. The ethics of artificial intelligence in pathology and laboratory medicine: principles and practice. *Acad Pathol.* 2021;**8**:2374289521990784. doi: 10.1177/2374289521990784, PMID 33644301, PMCID PMC7894680.
16. Vought RT, Office of Management and Budget. Memorandum for the heads of executive departments and agencies: guidance for regulation of artificial intelligence applications. *White House memo.* Jan 2020;**7**:1–15.
17. Ailia MJ, Thakur N, Abdul-Ghafar J, Jung CK, Yim K, Chong Y. Current trend of artificial intelligence patents in digital pathology: A systematic evaluation of the patent landscape. *Cancers.* 2022;**14**(10):2400. doi: 10.3390/cancers14102400, PMID 35626006.
18. Hida AI, Omanovic D, Pedersen L, et al. Automated assessment of Ki-67 in breast cancer: the utility of digital image analysis using virtual triple staining and whole slide imaging. *Histopathology.* 2020;**77**(3):471–80. doi: 10.1111/his.14140, PMID 32578891.
19. Saha M, Chakraborty C, Arun I, Ahmed R, Chatterjee S. An advanced deep learning approach for Ki-67 stained hotspot detection and proliferation rate scoring for prognostic evaluation of breast cancer. *Sci Rep.* 2017;**7**(1):3213. doi: 10.1038/s41598-017-03405-5, PMID 28607456.

- 725 20. Yousif M, van Diest PJ, Laurinavicius A, et al. Artificial intelligence applied to breast pathology.  
726 *Virchows Arch.* 2022;**480(1)**:191–209. doi: 10.1007/s00428-021-03213-3, PMID 34791536.  
727
- 728 21. Xu H, Park S, Hwang TH. Computerized classification of prostate cancer Gleason scores from  
729 whole slide images. *IEEE ACM Trans Comput Biol Bioinform.* 2020;**17(6)**:1871–82. doi:  
730 10.1109/TCBB.2019.2941195, PMID 31536012.  
731
- 732 22. Bulten W, Pinckaers H, van Boven H, et al. Automated deep-learning system for Gleason  
733 grading of prostate cancer using biopsies: a diagnostic study. *Lancet Oncol.* 2020;**21(2)**:233–41. doi:  
734 10.1016/S1470-2045(19)30739-9, PMID 31926805.  
735
- 736 23. Nagpal K, Foote D, Liu Y, et al. Development and validation of a deep learning algorithm for  
737 improving Gleason scoring of prostate cancer. *NPJ Digit Med.* 2019;**2**:48. doi: 10.1038/s41746-019-  
738 0112-2, PMID 31304394.  
739
- 740 24. Ström P, Kartasalo K, Olsson H, et al. Artificial intelligence for diagnosis and grading of prostate  
741 cancer in biopsies: a population-based, diagnostic study. *Lancet Oncol.* 2020;**21(2)**:222–32. doi:  
742 10.1016/S1470-2045(19)30738-7, PMID 31926806.  
743
- 744 25. Pantanowitz L, Quiroga-Garza GM, Bien L, et al. An artificial intelligence algorithm for prostate  
745 cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and  
746 deployment study. *Lancet Digit Health.* 2020;**2(8)**:e407–16. doi: 10.1016/S2589-7500(20)30159-X,  
747 PMID 33328045.  
748
- 749 26. Steiner DF, MacDonald R, Liu Y, et al. Impact of deep learning assistance on the  
750 histopathologic review of lymph nodes for metastatic breast cancer. *Am J Surg Pathol.*  
751 2018;**42(12)**:1636–46. doi: 10.1097/PAS.0000000000001151, PMID 30312179.  
752
- 753 27. Ehteshami Bejnordi B, Veta M, Johannes van Diest P, et al. Diagnostic assessment of deep  
754 learning algorithms for detection of lymph node metastases in women with breast cancer. *JAMA.*  
755 2017;**318(22)**:2199–210. doi: 10.1001/jama.2017.14585, PMID 29234806.  
756
- 757 28. Campanella G, Hanna MG, Geneslaw L, et al. Clinical-grade computational pathology using  
758 weakly supervised deep learning on whole slide images. *Nat Med.* 2019;**25(8)**:1301–9. doi:  
759 10.1038/s41591-019-0508-1, PMID 31308507.  
760
- 761 29. Yousif M, van Diest PJ, Laurinavicius A, et al. Artificial intelligence applied to breast pathology.  
762 *Virchows Arch.* 2022;**480(1)**:191–209. doi: 10.1007/s00428-021-03213-3, PMID 34791536.  
763
- 764 30. Haymond S, McCudden C. Rise of the machines: artificial intelligence and the Clinical  
765 Laboratory. *J Appl Lab Med.* 2021;**6(6)**:1640–54. doi: 10.1093/jalm/jfab075, PMID 34379752.  
766
- 767 31. Haghghat M, Browning L, Sirinukunwattana K, et al. Automated quality assessment of large  
768 digitised histology cohorts by artificial intelligence. *Sci Rep.* 2022;**12(1)**:5002. doi: 10.1038/s41598-022-  
769 08351-5, PMID 35322056.  
770
- 771 32. Janowczyk A, Zuo R, Gilmore H, Feldman M, Madabhushi A. HistoQC: an open-source quality  
772 control tool for digital pathology slides. *JCO Clin Cancer Inform.* 2019;**3**:1–7. doi:  
773 10.1200/CCI.18.00157, PMID 30990737, PMCID PMC6552675.  
774



- 775 33. Mitchell BR, Cohen MC, Cohen S. Dealing with multi-dimensional data and the burden of  
776 annotation: easing the burden of annotation. *Am J Pathol.* 2021;**191(10)**:1709–16. doi:  
777 10.1016/j.ajpath.2021.05.023, PMID 34129843.  
778
- 779 34. Sarwar S, Dent A, Faust K, et al. Physician perspectives on integration of artificial intelligence  
780 into diagnostic pathology. *NPJ Digit Med.* 2019;**2**:28. doi: 10.1038/s41746-019-0106-0, PMID  
781 31304375.  
782
- 783 35. Cheng JY, Abel JT, Balis UGJ, McClintock DS, Pantanowitz L. Challenges in the development,  
784 deployment, and regulation of artificial intelligence in anatomic pathology. *Am J Pathol.*  
785 2021;**191(10)**:1684–92. doi: 10.1016/j.ajpath.2020.10.018, PMID 33245914.  
786
- 787 36. Tizhoosh HR, Pantanowitz L. Artificial intelligence and digital pathology: challenges and  
788 opportunities. *J Pathol Inform.* 2018;**9**:38. doi: 10.4103/jpi.jpi\_53\_18, PMID 30607305.  
789
- 790 37. Steiner DF, Chen PC, Mermel CH. Closing the translation gap: AI applications in digital  
791 pathology. *Biochim Biophys Acta Rev Cancer.* 2021;**1875(1)**:188452. doi:  
792 10.1016/j.bbcan.2020.188452, PMID 33065195.  
793
- 794 38. Sobhani F, Robinson R, Hamidinekoo A, Roxanis I, Somaiah N, Yuan Y. Artificial intelligence  
795 and digital pathology: opportunities and implications for immuno-oncology. *Biochim Biophys Acta Rev*  
796 *Cancer.* 2021;**1875(2)**:188520. doi: 10.1016/j.bbcan.2021.188520, PMID 33561505.  
797
- 798 39. Serag A, Ion-Margineanu A, Qureshi H, et al. Translational AI and deep learning in diagnostic  
799 pathology. *Front Med (Lausanne).* 2019;**6**:185. doi: 10.3389/fmed.2019.00185, PMID 31632973.  
800
- 801 40. Rakha EA, Toss M, Shiino S, et al. Current and future applications of artificial intelligence in  
802 pathology: a clinical perspective. *J Clin Pathol.* 2021;**74(7)**:409–14. doi: 10.1136/jclinpath-2020-206908,  
803 PMID 32763920.  
804
- 805 41. Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital  
806 pathology — new tools for diagnosis and precision oncology. *Nat Rev Clin Oncol.* 2019;**16(11)**:703–15.  
807 doi: 10.1038/s41571-019-0252-y, PMID 31399699.  
808
- 809 42. Flach RN, Fransen NL, Sonnen AFP, et al. Implementation of artificial intelligence in diagnostic  
810 practice as a next step after going digital: the UMC Utrecht perspective. *Diagnostics (Basel).*  
811 2022;**12(5)**:1042. doi: 10.3390/diagnostics12051042, PMID 35626198.  
812
- 813 43. Farris AB, Vizcarra J, Amgad M, Cooper LAD, Gutman D, Hogan J. Artificial intelligence and  
814 algorithmic computational pathology: an introduction with renal allograft examples. *Histopathology.*  
815 2021;**78(6)**:791–804. doi: 10.1111/his.14304. PMID 33211332.  
816
- 817 44. Kriegsmann M, Haag C, Weis CA, et al. Deep learning for the classification of small-cell and  
818 non-small-cell lung cancer. *Cancers (Basel).* 2020;**12(6)**:1604. doi: 10.3390/cancers12061604, PMID  
819 32560475.  
820
- 821 45. van der Laak J, Litjens G, Ciompi F. Deep learning in histopathology: the path to the clinic. *Nat*  
822 *Med.* 2021;**27(5)**:775–84. doi: 10.1038/s41591-021-01343-4. PMID 33990804.  
823
- 824 46. Homeyer A, Lotz J, Schwen LO, et al. Artificial intelligence in pathology: from prototype to  
825 product. *J Pathol Inform.* 2021;**12**:13. doi: 10.4103/jpi.jpi\_84\_20, PMID 34012717.  
826

- 827 47. Försch S, Klauschen F, Hufnagl P, Roth W. Artificial intelligence in pathology. *Dtsch Arztebl Int.*  
828 2021;**118(12)**:194–204. doi: 10.3238/arztebl.m2021.0011, PMID 34024323.  
829
- 830 48. Kearney SJ, Lowe A, Lennerz JK, et al. Bridging the gap: the critical role of regulatory affairs  
831 and clinical affairs in the total product life cycle of pathology imaging devices and software. *Front Med*  
832 (*Lausanne*). 2021;**8**:765385. doi: 10.3389/fmed.2021.765385, PMID 34869473.  
833
- 834 49. Chauhan C, Gullapalli RR. Ethics of AI in pathology: current paradigms and emerging issues.  
835 *Am J Pathol.* 2021;**191(10)**:1673–83. doi: 10.1016/j.ajpath.2021.06.011, PMID 34252382.  
836
- 837 50. Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its  
838 appropriateness. *World J Methodol.* 2021;**11(4)**:116–29. doi: 10.5662/wjm.v11.i4.116, PMID 34322364.  
839
- 840 51. Rowe G, Wright G. The Delphi technique as a forecasting tool: issues and analysis. *Int J*  
841 *Forecast.* 1999;**15(4)**:353–75. doi: 10.1016/S0169-2070(99)00018-7.  
842
- 843 52. Jünger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on Conducting and Reporting  
844 Delphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic  
845 review. *Palliat Med.* 2017;**31(8)**:684–706. doi: 10.1177/0269216317690685, PMID 28190381.  
846
- 847 53. Goodman CM. The Delphi technique: a critique. *J Adv Nurs.* 1987;**12(6)**:729–34. doi:  
848 10.1111/j.1365-2648.1987.tb01376.x, PMID 3320139.  
849
- 850 54. Dalkey NC, Helmer O. An experimental application of the Delphi method to the use of experts.  
851 *Manag Sci.* 1963;**9(3)**:458–67. doi: 10.1287/mnsc.9.3.458.  
852
- 853 55. De Vet E, Brug J, De Nooijer J, Dijkstra A, De Vries NK. Determinants of forward stage  
854 transitions: a Delphi study. *Health Educ Res.* 2005;**20(2)**:195–205. doi: 10.1093/her/cyg111, PMID  
855 15328302.  
856
- 857 56. von der Gracht HA. Consensus measurement in Delphi studies. *Technol Forecast Soc Change.*  
858 2012;**79(8)**:1525–36. doi: 10.1016/j.techfore.2012.04.013.  
859
- 860 57. Holmström O, Linder N, Kaingu H, et al. Point-of-care digital cytology with artificial intelligence  
861 for cervical cancer screening in a resource-limited setting. *JAMA Netw Open.* 2021;**4(3)**:e211740. doi:  
862 10.1001/jamanetworkopen.2021.1740, PMID 33729503.  
863
- 864 58. Cheng S, Liu S, Yu J, et al. Robust whole slide image analysis for cervical cancer screening  
865 using deep learning. *Nat Commun.* 2021;**12(1)**:5639. doi: 10.1038/s41467-021-25296-x, PMID  
866 34561435.  
867
- 868 59. Nasir-Moin M, Suriawinata AA, Ren B, et al. Evaluation of an artificial intelligence-augmented  
869 digital system for histologic classification of colorectal polyps. *JAMA Netw Open.* 2021;**4(11)**:e2135271.  
870 doi: 10.1001/jamanetworkopen.2021.35271, PMID 34792588.  
871
- 872 60. Iizuka O, Kanavati F, Kato K, Rambeau M, Arihiro K, Tsuneki M. Deep learning models for  
873 histopathological classification of gastric and colonic epithelial tumours. *Sci Rep.* 2020;**10(1)**:1504. doi:  
874 10.1038/s41598-020-58467-9, PMID 32001752.  
875
- 876 61. Forlano R, Mullish BH, Giannakeas N, et al. High-throughput, machine learning–based  
877 quantification of steatosis, inflammation, ballooning, and fibrosis in biopsies from patients with



- 878 nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol*. 2020;**18(9)**:2081–2090.e9. doi:  
879 10.1016/j.cgh.2019.12.025, PMID 31887451.
- 880
- 881 62. Heinemann F, Birk G, Stierstorfer B. Deep learning enables pathologist-like scoring of NASH  
882 models. *Sci Rep*. 2019;**9(1)**:18454. doi: 10.1038/s41598-019-54904-6, PMID 31804575.
- 883
- 884 63. Chatrian A, Colling RT, Browning L, et al. Artificial intelligence for advance requesting of  
885 immunohistochemistry in diagnostically uncertain prostate biopsies. *Mod Pathol*. 2021;**34(9)**:1780–94.  
886 doi: 10.1038/s41379-021-00826-6, PMID 34017063.
- 887
- 888 64. Baxi V, Edwards R, Montalto M, Saha S. Digital pathology and artificial intelligence in  
889 translational medicine and clinical practice. *Mod Pathol*. 2022;**35(1)**:23–32. doi: 10.1038/s41379-021-  
890 00919-2, PMID 34611303.
- 891
- 892 65. Wulczyn E, Steiner DF, Moran M, et al. Interpretable survival prediction for colorectal cancer  
893 using deep learning. *NPJ Digit Med*. 2021;**4(1)**:71. doi: 10.1038/s41746-021-00427-2, PMID 33875798.
- 894
- 895 66. Sobhani F, Robinson R, Hamidinekoo A, Roxanis I, Somaiah N, Yuan Yinyin. Artificial  
896 intelligence and digital pathology: opportunities and implications for immuno-oncology. *Biochim Biophys*  
897 *Acta Rev Cancer*. 2021;**1875(2)**:188520, ISSN 0304-419X. doi: 10.1016/j.bbcan.2021.188520, PMID  
898 33561505.
- 899
- 900 67. Heinz CN, Echle A, Foersch S, Bychkov A, Kather JN. The future of artificial intelligence in  
901 digital pathology – results of a survey across stakeholder groups. *Histopathology*. 2022;**80(7)**:1121–7.  
902 doi: 10.1111/his.14659, PMID 35373378.
- 903
- 904 68. Kiani A, Uyumazturk B, Rajpurkar P, et al. Impact of a deep learning assistant on the  
905 histopathologic classification of liver cancer. *NPJ Digit Med*. 2020;**3**:23. doi: 10.1038/s41746-020-0232-  
906 8, PMID 32140566.
- 907
- 908 69. Zhou S, Marklund H, Blaha O, et al. Deep learning assistance for the histopathologic diagnosis  
909 of *Helicobacter pylori*. *Intell-Based Med*. 2020;**1–2**:(100004). doi: 10.1016/j.ibmed.2020.100004.
- 910
- 911 70. Dov D, Assaad S, Syedibrahim A, et al. A hybrid human-machine learning approach for  
912 screening prostate biopsies can improve clinical efficiency without compromising diagnostic accuracy.  
913 *Arch Pathol Lab Med*. 2022;**146(6)**:727–34. doi: 10.5858/arpa.2020-0850-OA, PMID 34591085.
- 914
- 915 71. Steiner DF, Nagpal K, Sayres R, et al. Evaluation of the use of combined artificial intelligence  
916 and pathologist assessment to review and grade prostate biopsies. *JAMA Netw Open*.  
917 2020;**3(11)**:e2023267. doi: 10.1001/jamanetworkopen.2020.23267, PMID 33180129.
- 918
- 919 72. Murphy K, Di Ruggiero E, Upshur R, et al. Artificial intelligence for good health: a scoping  
920 review of the ethics literature. *BMC Med Ethics*. 2021;**22(1)**:14. doi: 10.1186/s12910-021-00577-8,  
921 PMID 33588803.
- 922
- 923 73. Marble HD, Huang R, Dudgeon SN, et al. A regulatory science initiative to harmonize and  
924 standardize digital pathology and machine learning processes to speed up clinical innovation to  
925 patients. *J Pathol Inform*. 2020;**11**:22. doi: 10.4103/jpi.jpi\_27\_20, PMID 33042601.
- 926
- 927